Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Sinovac Biotech Ltd (SVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/31/2025: SVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 642.44M USD | Price to earnings Ratio 6.66 | 1Y Target Price 3.52 |
Price to earnings Ratio 6.66 | 1Y Target Price 3.52 | ||
Volume (30-day avg) - | Beta 0.06 | 52 Weeks Range 6.47 - 6.47 | Updated Date 02/21/2025 |
52 Weeks Range 6.47 - 6.47 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.97 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.61% | Operating Margin (TTM) 42.26% |
Management Effectiveness
Return on Assets (TTM) 11.46% | Return on Equity (TTM) 25.16% |
Valuation
Trailing PE 6.66 | Forward PE - | Enterprise Value 297087285 | Price to Sales(TTM) 1.83 |
Enterprise Value 297087285 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.04 | Shares Outstanding 99294704 | Shares Floating 59508332 |
Shares Outstanding 99294704 | Shares Floating 59508332 | ||
Percent Insiders 51.42 | Percent Institutions 32.02 |
AI Summary
Sinovac Biotech Ltd. (SVA)
Company Profile:
Detailed history and background:
Established in 1994, Sinovac Biotech Ltd. is a China-based biopharmaceutical company dedicated to researching, developing, manufacturing, and selling vaccines. Initially focusing on animal health, Sinovac transitioned to human vaccines in 2004, gaining recognition for its innovative and affordable vaccines. The company has expanded globally, with operations in China, Brazil, and other countries.
Core business areas:
- Vaccines: Sinovac develops and manufactures vaccines for various infectious diseases, including COVID-19 (CoronaVac), influenza (Healive), and hepatitis A & B (Healive/Hecolin).
- Blood products: The company also produces blood products like human albumin and rabies immunoglobulin.
Leadership and corporate structure:
- Chairman and CEO: Weidong Yin
- President: Junfeng Yue
- Executive Director and Chief Technology Officer: Xiaoming Yang
Top Products and Market Share:
Top products:
- CoronaVac: A COVID-19 vaccine based on an inactivated virus, approved for use in over 50 countries and regions.
- Healive: Flu vaccines for adults and children.
- Hecolin: Hepatitis A & B combination vaccine.
Market share:
- Global: CoronaVac holds a significant market share in emerging countries, contributing to over 40% of China's total COVID-19 vaccine administration.
- US: CoronaVac holds a relatively smaller market share in the US compared to other approved vaccines.
Competition:
- Pfizer/BioNTech (PFE, BNTX): Leading mRNA-based COVID-19 vaccine developers with significant market share in the US.
- Moderna (MRNA): Another major mRNA-based COVID-19 vaccine developer with a growing market presence.
- Johnson & Johnson (JNJ): Developed a vector-based COVID-19 vaccine with a presence in the US market.
Total Addressable Market:
The global vaccine market is expected to reach $71.9 billion by 2025, with the COVID-19 segment playing a significant role. Emerging economies present a vast opportunity for vaccine manufacturers like Sinovac.
Financial Performance:
Recent financial statements:
- Revenue: Revenue has grown significantly in recent years due to COVID-19 vaccine sales.
- Net income: Net income has also experienced substantial growth, reflecting the company's profitability.
- Profit margins: Profit margins have remained healthy, showcasing effective cost management.
- Earnings per share (EPS): EPS has increased steadily over the past few years.
Year-over-year comparison:
Sinovac has consistently shown strong year-over-year financial performance, primarily driven by CoronaVac sales.
Cash flow and balance sheet:
The company has a healthy cash flow and a strong balance sheet, indicating financial stability.
Dividends and Shareholder Returns:
Dividend history:
Sinovac has a history of paying dividends, with a recent yield of 0.49%.
Shareholder returns:
Shareholder returns have been positive in recent years, reflecting the company's growth and profitability.
Growth Trajectory:
Historical growth:
Sinovac has experienced significant historical growth, driven by the COVID-19 pandemic and increasing demand for vaccines.
Future projections:
The company's future growth prospects depend on the continued demand for COVID-19 vaccines and the success of its new product pipeline.
Market Dynamics:
Industry trends:
The vaccine industry is characterized by constant innovation, technological advancements, and increasing competition.
Company positioning:
Sinovac is well-positioned in the industry due to its established presence, focus on emerging markets, and affordable vaccine offerings.
Competitors:
The company faces competition from large pharmaceutical companies with significant resources and established market presence.
Potential Challenges and Opportunities:
Key challenges:
- Maintaining market share in a competitive environment.
- Managing supply chain disruptions and ensuring vaccine availability.
- Developing new products and adapting to evolving market demands.
Potential opportunities:
- Expanding into new markets, particularly in emerging economies.
- Diversifying product offerings beyond COVID-19 vaccines.
- Collaborating with other companies to develop innovative vaccines.
About Sinovac Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-11-03 | Chairman, CEO, Pres, MD, GM & Sec. Dr. Weidong Yin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1959 | Website http://www.sinovacbio.com |
Full time employees 1959 | Website http://www.sinovacbio.com | ||
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.